椎间盘内髓核同种异体移植与假手术对照治疗退变性椎间盘疾病相关椎间盘源性腰痛的安全性和有效性:随机临床试验研究方案
这是一项随机、双盲、假手术对照、多中心临床试验方案,旨在评估椎间盘内注射髓核同种异体移植物(VIA Disc NP)治疗退变性椎间盘疾病相关椎间盘源性腰痛的安全性和有效性。受试者为22至85岁、MRI确诊腰椎退变性椎间盘疾病(改良Pfirrmann分级3-7级)、轴性腰痛至少6个月且保守治疗无效的患者,按2:1随机接受单次VIA Disc NP注射或假手术。主要终点为12个月时腰痛严重程度降低≥30%的受试者比例。
要点
- 纳入标准包括22-85岁、MRI确诊改良Pfirrmann 3-7级、轴性腰痛≥6个月且保守治疗无效。
- 主要疗效终点为12个月时腰痛严重程度降低≥30%的受试者比例。
- 假手术组受试者若12个月时仍有症状,可交叉接受活性治疗。
核心结论
- 该试验旨在为补充髓核同种异体移植治疗中重度腰椎椎间盘源性腰痛提供1级安全性和有效性证据。
研究设计与样本
- 随机、双盲、假手术对照、多中心临床试验,评估VIA Disc NP的安全性和有效性。
- 受试者按2:1比例随机接受单次VIA Disc NP注射或假手术。
- 纳入标准包括22至85岁、MRI确诊腰椎退变性椎间盘疾病(改良Pfirrmann分级3-7级)、轴性腰痛至少6个月且保守治疗无效的功能障碍患者。
- 试验已在Clinical.gov注册(标识符:NCT06778447),注册日期2025年1月16日。
关键数值与推荐
- 主要疗效终点为12个月时腰痛严重程度降低≥30%的受试者比例。
- 次要终点包括功能改善(ODI)、生活质量指标(EQ-5D-5L、PGIC)和阿片类药物减少。
- 假手术组受试者若12个月时仍有症状,可交叉接受活性治疗。
临床怎么用
- 若试验成功,该方法可能为脊柱融合或椎间盘置换提供一种微创、持久且保留结构的治疗替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic low-back pain is a leading cause of global disability, with degenerative disc disease (DDD) recognized as a common structural contributor. While conservative therapies may provide temporary symptom relief, they do not address the underlying degeneration of the intervertebral disc. Surgical interventions, such as spinal fusion or total disc replacement, are invasive procedures that permanently alter the anatomical structure of the vertebral motion segment. Minimally invasive intradiscal therapies have the potential to bridge the treatment gap between non-surgical management and surgery. Intradiscal delivery of nucleus pulposus (NP) allograft is intended to structurally supplement the degenerating disc and restore native disc function. Preliminary studies have suggested that a single intradiscal administration of NP allograft (VIA Disc NP) may improve pain and function in patients with lumbar discogenic pain. METHODS: This is a randomized, double-blind, sham-controlled, multi-center clinical trial designed to evaluate the safety and efficacy of VIA Disc NP. Eligible participants are 22 to 85 years of age with MRI-confirmed lumbar DDD (modified Pfirrmann grade 3-7), axial low-back pain of at least 6 months' duration, and functional impairment unresponsive to conservative treatment. Participants are randomized in a 2:1 ratio to receive either a single injection of VIA Disc NP or a sham procedure. The primary efficacy endpoint of this superiority trial is the proportion of participants achieving a ≥ 30% reduction in back pain severity at 12 months. Secondary endpoints include functional improvement (ODI), quality-of-life measures (EQ-5D-5L, PGIC), and opioid reduction. Sham participants who remain symptomatic at 12 months may cross over to receive active treatment. DISCUSSION: This trial will provide level-1 evidence of the safety and efficacy of supplemental NP allograft therapy in patients with moderate to severe lumbar discogenic pain. If successful, this approach may offer a minimally invasive, durable, and structure-preserving treatment alternative to spinal fusion or disc arthroplasty in a population with limited therapeutic options. TRIAL REGISTRATION: This trial is prospectively registered at ClinicalTrials.gov (Identifier: NCT06778447). Registered on January 16, 2025.
引用
- Deer TR, Nunley PD, Naidu RK, et al. Safety and efficacy of intradiscal nucleus pulposus allograft versus sham for lumbar discogenic pain associated with degenerative disc disease: study protocol for a randomized clinical trial. Trials. 2026. PMID: 42260665. doi:10.1186/s13063-026-09826-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。